Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I am confident that even if they don’t hit the 240, the FDA will accept the safety and efficacy data from the 500 CHEMSAT 2.0 treatments from the EU to offset any enrollment deficiencies.
Of course, my opinion only.
Sam, would it hurt if earnings come out and they include guidance and update on CHEMSAT 2.0 and the FOCUS trial, strong European revenue and management discussion about the timeline for filing the NDA with the FDA? All possible, IMO.
How’s that for a dose of perspective?
A RS doesn’t mean squat if they start flexing a little muscle in the process.
This is 2018, not 2013, 2014, 2015, 2016 or 2017. It’s damn near go-time.
There isn’t a do-over option like one of Sam’s wormholes, is there? I’m kinda sorta thinking I’d like to go back to October 2017 to rethink strategy.
Off Topic: Colt Seivers was a bad a$$.
If Sam is Jenny Simpson, I at selling all 530,000 at tomorrow’s open, regardless of price.
Thereafter, I will self-flagellate with a rusty barbed wire and then jump into an active volcano wearing only a pair of leather chaps.
That, by the way, would go a very long way in explaining things...
Gotta vote on it first. At least a month away.
An interesting read.
MEMORANDUM OF UNDERSTANDING BETWEEN THE U.S. SECURITIES AND EXCHANGE COMMISSION & THE GOVERNMENTOF THE STATE OF ISRAEL CONCERNING CONSULTATION. AND COOPERATION IN THE ADMINISTRATION AND ENFORCEMENT OF SECURITIES LAWS
https://www.sec.gov/about/offices/oia/oia_bilateral/israel.pdf
Serious question:
What do I make of someone who just created his/her profile two weeks ago and has written 22 DCTH posts, all trashing DCTH and today another lording over the fact it is heading south?
I don't have the answer, just as I don't have the answer for someone such as yourself. I don't enjoy what is happening.
There will come a time in the not too distant future where our roles may be reversed. If that comes to pass, I can assure you of one thing: I won't spend a second thinking about you or the countless others who've come and gone.
But I agree. Don’t know much about Clay, but his followers are animals.
I don’t think that he did. I mean, unless he did and didn’t post to the thread (or I just missed it)?
Last blowup had high search traffic from Israel and Canada.
HULK NO SAY PRESENT DAY DCTH $422 PER SHARE.
Ha. I hope someone is probing the perimeter and recording these 10,000 share buys, with MAXM not budging.
Where are these shares coming from?
Good point. I think the discussion has tacked too negative the past couple of weeks (and with good reason, given the PPS). What impact, if any, would a massive short attack have on DCTH? If you recall, two weeks ago the shorts choppered in a bunch of posters and the PPS got bushwacked even further.
Just keeping open all reasons why the PPS has tanked lately. Could it be possible a coordinated and carefully orchestrated short attack has hijacked the narrative? The FINRA report will confirm this in another week. But until then, it merits discussion, IMO.
And no, i am NOT trying to defend the lack of transparency by DCTH. Just want to look at all possible scenarios.
Delcath Enhances Board of Directors With Appointment of Industry Veteran, Dr. Simon Pedder
NEW YORK, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that Simon Pedder, Ph.D., a scientist and pharmaceutical executive with a greater than 30-year career in drug development, has joined the Delcath Board of Directors effective November 14, 2017.
Dr. Pedder currently serves as Chief Business and Strategy Officer at Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. During his long career in drug development, Dr. Pedder has held several leadership positions including President and CEO of Cellectar Biosciences, President and CEO of Chelsea Therapeutics, Executive Officer and Vice President of Oncology Pharma Business at Hoffmann-LaRoche, Life Cycle Leader and Global Project Leader of Pegasys/IFN and Head of the Hepatitis Franchise at Hoffmann-LaRoche.
http://delcath.com/reuters-news/?id=2317872
PERSPECTIVE.
EARNINGS ARE RIGHT AROUND THE CORNER. I WOULD NOT WANT AN EQUITY SHORT INTEREST POSITION WHEN THE 10K DROPS.
DCTH is smack in the middle of a Phase 3 clinical trial with the FDA on a SPA for a therapy that has the potential to address multiple types of cancer in a $2.5B market space.
Delcath Announces Third Quarter 2017 Financial Results
Highlights from the third quarter of 2017 and recent weeks include:
• Revenue for the third quarter of 2017 increased 75% to $0.7 million from $0.4 million in the prior-year quarter;
• Revenue for the first nine months of 2017 increased 53% to $2.0 million from $1.3 million in the prior-year period;
• Medical University of Hannover achieved its 100th CHEMOSAT treatment milestone; over 450 commercial CHEMOSAT procedures have been performed in Europe;
• Positive results from a single institution study of CHEMOSAT filtration efficiency were presented at 2017 CIRSE annual meeting in September
The current PPS is terrible, the technology is not.
http://delcath.com/reuters-news/?id=2317164
Perspective.
Delcath Announces Preliminary Safety Analysis for Phase 3 Focus Trial
“The DSMB’s recommendation to proceed without modification with the FOCUS Trial as planned confirms our own observations of the safety profile of PHP therapy based on prior research and our commercial experience with CHEMOSAT in Europe,” said Jennifer K. Simpson, Ph.D., MSN, CRNP President and CEO of Delcath. “Importantly, this initial independent evaluation of the safety profile of melphalan/HDS used the Generation Two filter configuration of the device and the current version of the procedure protocol, and so provides confidence in both our product and procedure. Given that safety concerns with the previous generation product and procedure were the primary issue in the FDA’s previous assessment, we are pleased to have successfully passed this important milestone.
http://delcath.com/reuters-news/?id=2323336
On Delcath’s 500th Commercial CHEMOSAT Treatment in Europe:
This is a meaningful milestone for Delcath, one that speaks to the belief physicians in Europe have developed in our product and this therapy for certain types of liver cancers. Our commercialization efforts in Europe have established a considerable body of published and presented research data that demonstrates the safety and efficacy of this therapy in appropriate patients. Further, Dutch Health Authorities recently included CHEMOSAT treatment in their published guidelines for ocular melanoma liver metastases, a step toward potential reimbursement coverage of CHEMOSAT in the Dutch market. We continue to leverage this experience to validate the safety and efficacy of the melphalan/Hepatic Delivery System (CHEMOSAT) in our clinical trials.”
http://delcath.com/reuters-news/?id=2330074
Wow. Where do I even start trying to unpack that fortune cookie of a post.
Were you whipping up froth EIGHT YEARS AGO when you predicted DCTH should be valued at $370 a share???
Now let’s put that number into context, shall we? The present value of $370 in 2010 is $422.39.
So had you written that post today, it would read:
“DCTH is worth $422.39/share”.
90 days from 9 Feb is May 10, 2018. They will burn through $4.65M in a two week period beginning May 11, 2018 and ending May 30, 2018?
Please explain your analysis. I am genuinely curious.
The Sec filing on Feb 9 specifically states the company has funding for 90 days WITHOUT proceeds from the placement. How do you reconcile that statement with your interpretation of them being totally out of cash by May? The math doesn’t add up.
Per the final placement SEC filing in 9 Feb, DCTH has funding through May 10, 2018 (9o days from date of filing) WITHOUT proceeds from the $4.65M from the placement.
Feel free read the schedule 14 and the final SEC. I could be reading the filings wrong, but that is a disconnect, IMO.
Oh that’s choice, JMMA. You fall out
Of the sky two weeks ago with a new iHub account.
What has taken place since you joined iHub? You said we were ‘touting’ (can’t really be touting if I did buy before the prior to reverse split); conjured a story whereby we said big things were coming? (please provide post #); next, you chastise Sam about voting yes for the split; then, a second post about how Sam should be sodomized (not sure how else, and I quote: “just bend over take one for the team”, could be construed).
Today you say that we called you ignorant (please post #). Which, in and of itself, kinda throws cold water on the premise of your post: why would we call you an ignorant investor because you were buying after a reverse split??? Seems a “touter” would encourage the purchase of shares, not discouraging, as you allege.
You do realize it isn’t nearly as fun for an open and honest exchange and debate about a stock, ON A STOCK MESSAGE BOARD, when, out of the blue, a newly minted iHub user shows up, cherry picks other posters opinions to fit a narrative the new user is trying to advance?
You are not the first, and you won't be the last.
Either way, I wish you the best.
Happy Investing!
I think every shareholder should take some time to read the article at the bottom of this post, as certain portions may be of interest to us.
And please, anyone with more robust knowledge of securities transactions, please feel free to chime in. This may be completely off-base and now, more than ever, I will caveat the following as MY OPINION ONLY. I may very well be completely off-base and wrong.
But if those 181M shares are part of a private investment in a public equity, known as a PIPE transaction, here are some concerns as highlighted in the linked article that could be applicable to DCTH. For the sake of clarity, I am stripping out any reference to Yahoo!, for which the article was written, and am replacing with COMPANY A:
1. While PIPE transactions are relatively common, such deals can also be controversial since they dilute existing shareholders ;
2. PIPE transaction would place a large block of shares into friendly hands;
3. As part of a PIPE deal, COMPANY A may undertake a leveraged recapitalization. In a leveraged recapitalization, a company typically borrows money and uses some of the PIPE proceeds to buy back a number of shares...more saliently, a leveraged recapitalization would raise the ownership percentage of these new private equity firms...thus, COMPANY A and PIPE investors would have a combined, controlling position in COMPANY A, allowing them to block any subsequent takeover or shareholder activism.
In DCTH's case, Ayerton owns 7.1%, Hudson Bay owns 2.65%, and the other 181M shares--if purchased by more than 8.5 entities and which could then bypass any Schedule 13 filing requirement, would add another 41.63% into the mix. Aggregate those percentages and you've got 51.04% ownership.
4. And here is the killer for COMPANY A's existing shareholders:
The reason is that a PIPE structured with a leveraged recapitalization would likely avoid triggering so-called Revlon duties under Delaware law. Revlon duties require a board to obtain the highest price reasonably available when a change of control happens at the company.
What I can't explain is why it seems MAXM and CDEL appear to continue to play a role in the PPS. Today, again, DCTH starts a move north and within minutes both move up to the front of the line and large chunks of shares are dropped on the market, which in turn, keeps the PPS in check. This was done at the $.08's, it was done at the $'04's, it was done at the $.02's and now it's being done at the $.015 range.
Worse, management continues to sit idle and do nothing. Except maybe pump out a head-scratching Schedule 14, which includes language about being viable only through May 2018, when the placement filing a week before indicated DCTH had money through 2018, without the $4.65M proceeds from the placement.
Shareholders need answers. And we need them directly from DCTH management.
https://dealbook.nytimes.com/2011/11/15/a-complicated-maneuver-for-control-of-yahoo/
At this point best avenue for shareholders, IMO, is to make demand under Delaware law and when DCTH declines, file a shareholder derivative suit.
From there it would be much easier to go after the company on BEHALF of the company.
We must state with particularity the harm done to the corporation, that would include executive salary, the total capitulate of social media presence since June 2017, the complete failure to address PPS as the stock tanked from $10.50 and seek, through discovery, the lack of transparency with the recent placement, and whether any previous buyout offers have been made to DCTH and why they were not taken to shareholders for a vote.
The Business Judgment Rule gives great deference to a company in how they run their company, but managements actions since August 2017 have opened to door for this type of action.
Is that a serious question to me? How would I know.
I just know that any owner of DCTH as of 9 February who posts on this iHub board better receive a form to vote.
Why do I get he feeling the call elk
Sound like something out of Crank Yankers?
They need to solicit votes from
All owners on this board.
Disclaimer: Sam doesn’t own the stock but has an insatiable interest in, at this point, DCTH wobbling sideways or flat out tanking.
I don’t think the question is unreasonable, Sam. Everyone has asked, you have never answered.
You can’t expect it unreasonable for people to ask when one day it’s going to hit $370 to the next you think that IF it is lucky to hit $.02, there will be a mass sell-off.
LoL. Well, I promise mine are not filled with death threats.
I do want to know why there is a 3 month discrepancy in the placement filing and the RS filing. They make it sound like DCTH will be out of money in the Schedule 14, yet the are on record of having financing through May 10 WITHOUT the $4.65M they just received.
Thank you. Is there a reason he does not respond to email? Don’t get me wrong, I am happy to call him. But it’s rude sending hundreds of emails and it get a single response.
Is that is name, Tom
Johnson?
Deflect all you want, now answer the question.
Answer the question, mr $370 pumper. Why are you here? You sold out. You are “retired” yet you post 24x7 on a stock you don’t own.
Now some people on this thread give you plenty of leeway. I don’t. It makes. I sense your purpose here. So
I ask again.
2020???
Sam, seriously. You now live in Fantasia.
You got lampooned off the yahoo DCTH Board, you NOT OWN DCTH, not only have you shamefully PUMPED DCTH saying it would hit $370, you are now making up FAKE DATES for FDA approval.
What is your agenda?
Answer our question: “Sam”
Lololol. I just started crying laughing as to one reason why it might spike. Well done. HHahahahha
Sam, I don’t really even understand close to 50% if what you post, and that’s okay with me.
But you don’t ever answer the questions we ask. They are very simple.
Correction to read ‘Clearly’.
No correction in CBS news new daytime business anchor Sam Rathers.
Nearly the pump to $370 didn’t work and no one is in the mood for Sam Rathers Reporting.
Agreed. Sam please explain why you are here.
Boy CDEL MAXM sure know how
to manipulate price, IMO.
PM me next time before hand and I
Will say me too!